Minutes of the meeting of Ayurvedic, Siddha and Unani Drugs Technical Advisory Board (ASUDTAB) held under the Chairmanship of Prof. (Dr.) Atul Goel, Director General of Health Services (DGHS), Government of India on 25th May, 2023, Room no. 445 A, NirmanBhawan, New Delhi.

A meeting of Ayurvedic, Siddha and Unani Drugs Technical Advisory Board (ASUDTAB) was held under the Chairmanship of **Prof. (Dr.) Atul Goel, Director General of Health Services (DGHS), Government of India** on 25thMay, 2023, Room No. 445 A, Nirman Bhawan, New Delhi on hybrid mode.

List of the Participants is placed at **Annexure I.**

At the outset Dr. Kousthubha Upadhyaya, Adviser (Ay.), Ministry of Ayush and Member-Secretary, ASUDTAB welcomed the Chairman, members of the Board, Special invitees & the participants and briefed the mandate & background of the board.

Dr. Anil Khurana highlighted that there is no representative of homoeopathy industry in the present ASUDTAB. In this regard, Member-secretary informed the board that the Homoeopathy and Sowa-Rigpa members were co-opted on regular basis till the tenure of this board with the approval of Chairman and Ministry of Ayush.

Chairman suggested that Ministry of Ayush may consider the representatives of Homoeopathy industry in the board as co-opted members. Further, he pointed out that if any member is absent in the three consecutive meetings of ASUDTAB, he/she may be replaced for the remaining tenure of the board. With the permission of Chairman, agenda-wise items were taken up for discussion.

Agenda-wise discussions and outcomes were as follows:

Agenda Item No. 1	**Approval of the minutes of the last meeting of ASUDTAB held on 27.06.2022.**

A copy of the approved minutes of the last meeting of ASUDTAB held on 27.06.2022 was circulated among the members/ invitee along with the approved agenda. In this regard, Dr. C.K. Katiyar commented that the decision of omitting Rule 170 was taken by ASUDTAB in its meeting of 15th March 2021 after recommendation by an expert committee of the Ministry of Ayush. Therefore, it was not appropriate to negate the previous decision of ASUDTAB in subsequent meeting dated 27.06.2022. Further, it was also not an agenda item in that meeting. The observation of Dr. V. G. Somani was in reference to ongoing discussion of the board. No other members had made their observations/ comments regarding Rule 170. The decision was indeed deferred as it was decided to redraft G.S.R. 437 dated 02.07.2021 in a single chapter in D & C Rules, 1945.

Considering the facts pointed out by the member, Chairman recommended to delete the recommendation ***"Omission of Rule 170 is not required"*** of ASUDTAB in its meeting held on 27.06.2022. ASUDTAB members unanimously agreed for this.

Agenda Item No. 2	**Action Taken Report (ATR) on the last recommendations of ASUDTAB**

Action taken report on the last recommendation of ASUDTAB meeting held on 26.07.2022 were presented before the Board and followings has been recommended –

S.no.	**Recommendations of Board**	**Action Taken Report**	**Observation/ recommendation of the board**
i.	*GSR No. 473(E) dated 02.07.2021 may be re-drafted as a separate part in Drugs & Cosmetics Rules, 1945 having all provisions related to Homoeopathy and Sowa-Rigpa system of medicine in light of recommendations of ASUDTAB at annexure II. Contents of remaining provisions of the said notification are deemed as approved by the ASUDTAB which will adopt as such.*	The agenda is once again placed as Agenda item -3.	Board observed that the matter may be discussed under Agenda item 3.
ii.	*An expert committee may be constituted by Ministry of Ayush to review or revisit the existing provisions of GMP, which will be placed before ASUDTAB.*	Ministry of Ayush vide O.M. no. T-11011/8/2021-DCC-Part(1) dated 15.09.2022 had constituted an Expert Committee to review or revisit the existing provisions of GMP for ASU&H drugs in Drugs & Cosmetic Act, 1940 and Rules there under. Suggestions from all the members of the committee has been sought. Work is under progress and final recommendation of the said expert committee will be placed before ASUDTAB for consideration.	Board recommended that the expert committee may submit its report within 03 months. Dr. Anil Khurana suggested to co-opt one more representative from industry Govt. PSU like HOMCO Kerala and IMPCL. Chairman recommended to consider the suggestion with consultation with Ministry of Ayush.
iii.	*With regard to submission of information under Schedule TA form, it is suggested that Ministry of Ayush may look into*	Schedule TA form regarding consumption of mercury, *Vijaya* and *Ahiphena* has been sought from the States/ UTs. However, Ministry is yet to receive	Board recommended that such data may directly be sought by Ministry of Ayush from ASU drug manufacturers or through

	compilation and analysis of data submitted under this provision for developing suitable policy initiatives.	completed data from all States/ UTs.	google form.
iv.	*Order no. T.13011/3/2019-DCC (Ayush) dated 29.07.2019 issued by Ministry of Ayush regarding consideration and acceptance of stability study data for fixing the shelf- life of ASU drugs under Rule 161-B of the Drugs & Cosmetics Rules 1945 for the purpose of grant of license and renewal of license in reference to GSR no. 789 (E) dated 18.08.20216 may be converted into Gazette Notification.*	The amendments in Rule 161 B is already notified under draft notification GSR No. 473(E) dated 02.07.2021 for Amendment in Drugs Rules 1945, published by the Ministry of Ayush. The same is placed for recommendation of ASUDTAB for final notification.	Agreed
v.	*An expert committee may be constituted by Ministry of Ayush to review/ revise the Schedule I Books of the Drugs and Cosmetics Act 1940 and Rules 1945. The committee may directly include books of Sowa-Rigpa recommended by Sub-committee for Sowa-Rigpa drugs under ASUDTAB respectively. The committee will review the existing Schedule-I and prepare a draft regarding the revision of Schedule I. The same will be placed before ASUDTAB.*	Ministry of Ayush vide O.M. no. T-11011/8/2021-DCC-Part(1) dated 22.08.2022 has constituted a expert Committee to review/ revise the Schedule I Books of the Drugs & Cosmetic Act, 1940 and Rules thereunder, with Director, PCIM&H as Member Secretary. Work is under progress and final recommendation of the said expert committee will be placed before ASUDTAB for consideration.	The member-secretary, ASUDTAB conveyed that the work of expert committee is in advance stage. Board recommended that Ministry may proceed with draft notification of the schedule books once recommended by the committee. Thereafter final draft along with the comments of stakeholders may be placed before the board.
vi.	*National Commission for Indian Medicine (NCISM) may be requested to direct all registered Ayush practitioner to clearly mention duration of intake of formulations containing Schedule E (1) drugs.*	NCISM had been requested to direct all registered Ayush practitioner to clearly mention duration of intake of formulations containing schedule E (1) drugs in their medical prescription vide letter no. T-11011/8/2021-DCC dated 17.08.2022.	Noted
vii.	*An expert committee may be constituted by Ministry of Ayush to review/ revise the Schedule E (1) under Rule*	Ministry of Ayush vide O.M. no. T-11011/8/2021-DCC-Part (1)dated 22.08.2022 has constituted an expert committee	The member-secretary, ASUDTAB conveyed that the work of expert committee is in advance stage. Board

	161 (2) of Drugs and Cosmetics Act Rules 1945, with representatives of Ayurveda Siddha Unani system of medicine along with a representative from NCISM. The committee will review the existing Schedule E (1) and prepare a draft regarding the revision of Schedule E (1) drugs. The same will be placed before ASUDTAB.	to review the existing Schedule E(1) and prepare a draft regarding the revision of Schedule E(1) drugs. Work is under progress and final recommendation of the said expert committee will be placed before ASUDTAB for consideration.	recommended that Ministry may proceed with draft notification of the schedule E (1) drugs once recommended by the committee. Thereafter final draft along with the comments of stakeholders may be placed before the board.
viii.	*Ministry of Ayush may once again approach Ministry of Environment, Forest and Climate Change with a request to device a mechanism for providing shed Deer Antler or Deer antler burnt Ash or any other animal products used in ASU industry from zoo/reserved forests through respective State Authorities when collection of such animal products do not cause any harm to the biodiversity.*	Ministry of Ayush vide D.O. letter no. T-13020/8/2020-DCC dated 16.08.2022 had requested to Ministry of Environment, Forest and Climate Changes to devise a mechanism for providing shed Deer Antler or Deer Antler burnt ash or any other animal products used in Ayush industry from zoo/ reserved forests through respective State authorities.	Vd. Santosh Nevpurkar highlighted that this matter is very important for Ayurveda practitioner. Board recommended that this matter may be taken up by Ministry of Ayush with Ministry of Environment, Forest and Climate Changes.
ix.	*Minutes of the ASUDTAB meeting should be posted on the website of Ministry of Ayush like practice followed by CDSCO also, for higher level of transparency.*	The minutes of the meeting of ASUDTAB held on 27.06.2022 has been uploaded on the website of Ministry of Ayush (https://main.ayush.gov.in/ayush-drugs/asudtab).	Board appreciated the efforts made in this regard.

Agenda Item No. 3	**Comments received on draft notification GSR No. 473(E) dated 02.07.2021 for Amendment in Drugs Rules 1945, published by the Ministry of Ayush.**

Member-Secretary, ASUDTAB apprised the board regarding the issues and challenges for making a separate part in Drugs & Cosmetics Rules, 1945 having all provisions related to Homoeopathy and Sowa-Rigpa system of medicine, which are as follows –

i. In the existing Rules, Homoeopathy Medicines are considered a special category of Drug under the broad heading of the definition of 'Drugs'. Accordingly, the provisions of

Homoeopathy Drugs follow the provisions related to Drugs other than Homoeopathy drugs and are mentioned under several headings and Part.

ii. Homoeopathic medicines are mentioned under the following Sections and Rules under the D&C Act and Rules respectively:

a) Standards of Homoeopathic Medicines under Schedule II of the Act.

b) Some Definitions under the Rules

c)Provisions for Import of Homoeopathic medicines the approving authority for which is DCGI

d) Provisions for Licensing of New Homoeopathic medicines the approving authority for which is DCGI

e) Separate Part for Sale of Homoeopathic Medicines.

f) Separate Part for Manufacture for Sale or for distribution of Homoeopathic Medicines

g) Separate Part for labelling and packing of Homoeopathic Medicines

h) Approval of Institutions for carrying out tests of Homoeopathic Medicines.

i) Separate forms for application and approval pertaining to Homoeopathic Medicines and schedule M1 for GMP of Homoeopathic Manufacturing Units.

j) Category under Schedule K for exemptions of Chapter IV of the Act.

iii. the enforcement of Homoeopathic Medicines in the States still lies with the Drug inspectors or controlling authority of the allopathy side for the reason mentioned at point 1 above and in some states separate licensing authority is notified under PART VI-A Sale or PART VII-A for Manufacture of Homoeopathic Medicines. These persons in place in the States would be required to be re-notified under the new Proposed PART/ Chapter.

iv. Reframing of the chapters etc. may require consultation with MoHFW and DTAB for legal clearance on the matter. Further, consultation may also be needed with the stakeholders like Homoeopathic Drugs Manufacturers/ Drug Controllers/Inspectors/Analysts/Importers/researchers to address the problems faced during testing, inspection and compliance by the manufacturers/importers with regard to Homoeopathic Medicines.

v. Already new Drugs, Medical Devices and Cosmetic Bill, 2023 is in advanced stage wherein homoeopathy and Sowa-Rigpa systems are holistically harmonized under common chapter along with other Ayush systems.

vi. Exercise of making separate part for Homoeopathy and Sowa-Rigpa system may requires comprehensive scrutiny of relevant provisions of D & C Rules, 1945. However, that effort may be avoided at this juncture as Rules are to be framed for the proposed new bill.

The representation of Dr. Pradeep Multani, President, Association of Manufacturers of Ayurvedic Medicines (AMAM) dated 10.04.2023 regarding Repealing Rule 170 of D&C Act was discussed in the meeting.

Dr. C.K. Katiyar informed that the provisions for prohibition of misleading advertisements are also covered under Drugs and Magic Remedies (OA), Act, 1954 and Consumer Protection

Act. Further, Dr. Asad Mueed also submitted that there are no requirements of Rule 170 as proper implementation of Drugs and Magic Remedies (OA), Act, 1954is sufficient and restriction on awareness spreading initiatives of industry will be against governments commitment for propagating Ayush systems.

Dr. Padma Gurmeet raised his concern that even though Sowa-Rigpa system was officially recognized under Ayush in 2010, the inclusion of this system under D & C Act, 1940 and rules thereunder is still pending. Member-Secretary informed all the members/ special invitee that for Sowa-Rigpa system, only definition part has been notified under G.S.R. 473(E) dated 02.07.2021, wherein reference to the First schedule is also mentioned. However, the draft notification with regard to addition of Sowa-Rigpa books in the first schedule is still not done. Therefore, it was opined that Sowa-Rigpa part from GSR No. 473(E) dated 02.07.2021 may be finally notified at later stage together with revised first schedule including Sowa-Rigpa books.

In this regard, following had been recommended by the board –

i. Separate part for Homoeopathy and Sowa-Rigpa system is not required at this juncture.
ii. Ministry of Ayush may finally notify the amendments in respect of Homoeopathy drugs as placed before the Board as Annexure-III of agenda, under concerned sections/ part of existing Drugs & Cosmetics Rules, 1945.
iii. to proceed with final notification for omission of Rule 170 and its related Forms mentioned in D & C Rules, 1945.
iv. For Sowa-Rigpa system, authoritative books may first be notified through draft gazette notification, as per **Annexure-II.** Thereafter, final notification of Sowa-Rigpa part as per G.S.R. No. 473(E) dated 02.07.2021 may be notified together.

The board reviewed the GSR No. 473(E) dated 02.07.2021 based on the its observations in the last meeting and recommended for final notification of already agreed provisions, as per Annexure-III.

Agenda Item No. 4	**Draft notification GSR No. 668(E) and 669(E) dated 23.09.2021 for Amendment in Drugs Rules 1945, published by the Ministry of Ayush**

Member-Secretary informed the board that Ministry of Ayush vide notification GSR No. 668(E) and 669(E) dated 23.09.2021 had notified regarding schedule books of homoeopathy and Import of New Homoeopathic medicines. The board considered the recommendations of committee constituted the Chairmanship of Dr. Sangeeta Duggal, Adviser (H.), Ministry of Ayush on stakeholders' comments.

Dr. Anil Khurana suggested that in the final notification for amendment of Rule 30 AA the subclause (2) point v i.e. "all nosodes and sarcodes unless certified otherwise by licensing authority under rule 21" should be removed as keeping this clause in the definition of new homoeopathic medicine will be self-contradictory to the already licensed nosodes and sarcodes

and those mentioned in authoritative homoeopathic literature. These suggestions were accepted by the Board.

The board recommended to include provision of 669(E) dated 23.09.2021 in final notification as per **Annexure-III** and final notification of schedule books of homoeopathy as per **Annexure-IV**.

Agenda Item No.5	**Representation of Ayush Drug manufacturers/ Industry/ Organizations**

i. Representation of Sri Navjeewan Rasayanshala, Jaipur Regulatory concerns of ASU Industry like availability of Schedule-I Books, Rule-169 of Drugs & Cosmetics Rules, 1945-reg.

With regard to representation of Sri Navjeewan Rasayanshala, Jaipur regarding availability of Schedule-I Books, member-secretary conveyed that the expert committee on first schedule, has already suggesting publication of all Schedule I books on the website. Therefore, this issue will be addressed accordingly. Regarding the matter of applicable list of Permitted Excipients, Dr. C.K. Katiyar observed that the lists of excipients mentioned under Rule 169 of D & C Rules, 1945 are dynamic in nature and these are already available in public domain on the respective websites of IP, FSSAI and BIS. Member Secretary also mentioned regarding the representation of Himalaya Drugs Co. regarding allowing of excipients of US pharmacopoeia for boosting exports. Dr. Rajeev Singh Raghuvanshi, DCG (I) mentioned that almost all excipients of USP are already available under I.P. Further, there is an enabling provisio under I.P. for adopting excipients from any other official pharmacopoeia that can be availed by the industry to include any such excipients.

Chairman suggested to disseminate the concerned provision among stakeholders for better awareness and implementation of the D & C Act and Rules. Further, he suggested that Ministry of Ayush may approach National Medical Library, New Delhi to create a dedicated repository/ section of Ayush related authoritative text books and other reference books.

ii. 2000% exorbitant hike in formulation product approval in the amended rule 153 A and 153 B of Drugs & Cosmetics Rule 1945 vide G.S.R. 716(E) dated 1st October 2021.

The board reviewed the representations of Ayush stakeholders regarding rule **153 A and 153 B** of Drugs & Cosmetics Rule 1945 vide G.S.R. 716(E) dated 1st October, 2021 and recommendation of board are as follows –

- The provisions related to all the systems of Ayush should be similar in respect of license fee. Further, the fees may be automatically revised once in 03 years in accordance with cost-inflation index.
- The fee for homoeopathy medicines as recommended by the expert committee for GSR No. 473(E) dated 02.07.2021 i.e. Rs. 2000/- for an application may be finally notified as per **Annexure III.**

- Advisories issued by the Ministry of Ayush to consider maximum 10 homoeopathy medicines (with all its potencies) per application for license, may be included in the draft notification.
- Fee for ASU medicines under Rule 153 of D&C Rules, 1945, "Rupees two thousand per product" may be replaced with "Rupees two hundred per product", may be included in the draft notification.

iii. Representation of Sh. Ramesh Kadyan, President, Micro & Small Scale Ayurvedic Manufacturers Association of Haryana (MSAMA), Haryana date 20.04.2023 regarding Request to Protect the Future of Micro ASU Industries by waiving off New Approval Fee & Retention Fee.

Representation of the Sh. Ramesh Kadyan for different fee structure for micro and small industries were reviewed by the board and the same was not considered as fee is already proposed to be reduced as Rs. 200/- per product, over and above the first 10 products of P&P ASU products.

iv. **Representation of Indian Homoeopathic Drug Manufacturers Forum regarding amendment of schedule K of Drug & Cosmetics Rules, 1945.**

Representation of the Indian Homoeopathic Drug Manufacturers Forum regarding amendment under the extent and subject to conditions specified in Schedule K, i.e. for removal of the words 'in Form 20C' and word 'retail' of point (ii), so that allopathy drugs wholesale dealers be also allowed to keep Homoeopathic Medicines for maintaining supply chain of Homoeopathic Medicines in allopathic retail stores. The matter was reviewed by the board and it has been recommended that as the matter involves changing the criteria of exemptions for dealers of medicines licensed under rule 61 in schedule K which is for allopathy drugs, it may be referred to DTAB for their deliberations/consideration.

Agenda Item No. 6	**Restricting name of use of Classical ASU Drugs to the category of ASU category of Drugs only**

The following issue raised by Sh. C.K. Katiyar, Member, ASUDTAB were discussed –

- *Mahabhringaraj Kesh Tail which has been manufactured using mineral oil instead of Til Tail but licensed under cosmetic category. This is an example of using name of a classical product Mahabhringaraj for Cosmetic product with entirely different composition.*
- *Second case is Chyawanprash Gummies, where the word Chyawanprash has been used, which is name of a classical Ayurvedic product. The format is Gummies and product has been licensed under FSSAI.*

Further, it was informed that in both the above cases names of Classical Ayurvedic products have been used for Non-Ayush Drug categories of Cosmetics or FSSAI. Ministry of Ayush has already banned the use of the name of Classical Ayurvedic products even for the proprietary ASU Drugs with Prefix and Suffix.

Dr. Prakash L Hegde submitted that there should be control over the selling of those medicines having classical names with different ingredients. Even it is observed that three or four classical formulations are combined together and new formulations are being prepared with a new name. This also should be taken very seriously as there may not be any proper research data findings or any other relevant information. Evidence should be produced that there is no interactions among these entirely different combinations.

ASUDTAB recommended that the matter of using name of ASU classical formulations in products licensed by FSSAI and CDSCO may be taken up by Ministry of Ayush with the respective organization.

Agenda Item No. 7	**Amendment in Rule 153 and 153 A of Drugs and Cosmetics Act 1940 and Rules 1945 vide gazette notification G.S.R. 341 (E) dated 24.04.2023**

All board memberswere informed that Ministry of Ayush vide notification G.S.R. 716 (E) dated 01.10.2021 had amended Rule 153 to Rule 156 of Drugs and Cosmetics Act 1940 and Rules 1945. Thereafter, vide gazette notification G.S.R. 341(E) dated 24.04.2023, following amendment has been made–

(a) in rule 153, in the second proviso, for the words "within eighteen months" the words "within twenty four months" shall be substituted;

(b) in Rule 153A, in the second proviso, for the words "within eighteen months", the words "within twenty four months" shall be substituted;

Member-secretary requested ASUDTAB board members for the ratification of G.S.R. 341 (E) dated 24.04.2023. The same has been agreed by all board members unanimously.

Further, Chairman suggested to change the name of the 'e-aushadhi portal' as this name may be confused with online sale of medicines through e-commerce platforms. He suggested to explore terms like "e.lic-ayush" portal for this purpose.

Agenda Item No.8	**Technical Committee on adopting new dosage forms under Ayush stream**

The draft prepared by the technical committee for adopting new dosage form under Ayush stream under the Chairmanship of Prof. S.K. Maulik were discussed in the meeting. Dr.

Rajeev Singh Raghuvanshi, DCG (I) informed that parameters are stringent in nature and may be reviewed.

Dr. Anil Khurana suggested to incorporate Homoeopathy System representative also in the said Committee or get the document framed vetted through circulation amongst Homoeopathic fraternity also.

In this regard, Member Secretary suggested that the guidelines may be notified for stakeholder comments and final view may be taken thereafter. Board recommended for notifying the guidelines for stakeholder consultation.

Agenda Item No.9	**Issue of manufacturing license by lease license owner for Ayurveda, Siddha and Unani drug categories.**

The Board observed that there is no explicit provision for lease licensing under Drugs & Cosmetics Act, 1940 and rules thereunder. Ministry of Ayush may issue an advisory to all State/ UTs to avoid granting of licenses under Form 25-Don the basis of lease agreements. For any eventuality for meeting the demand, there is already provision of loan licensing under Drugs & Cosmetics Act, 1940 and rules thereunder.

Agenda Item No.10	**Any other item with the permission of the Chair**

Member Secretary informed the board that Ministry of Ayush has received various representation demanding clear demarcation of ASU medicines containing non-vegetarian ingredients. The board suggested that this is an essential requirement that should be considered. However, it is difficult to define which is to be considered as vegetarian or non-vegetarian as interpretation depends on various religious, ethical and regional consideration.

The Board recommended Ministry of Ayush may constitute a committee of experts to deliberate and suggest on this issue.

The meeting ended with vote of thanks to the Chairman.

******

Annexure I

List of participants of ASUDTAB meeting held on 25.05.2023 -

S. No.	Name of ASUDTAB member
1.	Prof. Dr. Atul Goel, The Director General of Health Services, (Chairman ASUDTAB) NirmanBhawan, New Delhi-110011
2.	Dr. Rajeev Singh Raghuvanshi, Drugs Controller General of India, FDA Bhawan, Kotla Road, ITO, Delhi-110002
3.	Dr. Kousthubha Upadhyaya, Adv.(Ay.), Ministry of Ayush, Member Secretary-ASUDTAB
4.	Director, Central Drugs Laboratory, 3, Kyd Street Kolkatta-700016
5.	Dr. Raman Mohan Singh, Government Analyst, Director, Pharmacopoeia Commission for Indian Medicine & Homoeopathy, Ghaziabad, U.P.
6.	Dr. Neeraj Tandon, Scientist-G and Head, Divisions of Publications & Information and Medicinal Plants, Indian Council of Medical Research, Ansari Nagar, New Delhi 110029
7.	Prof. Pulok K. Mukherjee, Director, Institute of Bio resources and Sustainable Development Manipur and Professor (on lien), Dept. of Pharmaceutical Technology, Jadavpur University, Kolkata - 700 032.
8.	Dr. Prakash Hegde, Department of Dravya Guna, Sri Dharmasthala Manjunatheswara College of Ayurveda and Hospital, Hassan
9.	Dr. C. K. Katiyar CEO Health Care (Technical) Emami Ltd, 687, Anandpur, EM Bypass, Kolkata-700 007
10.	Dr. Sumit Nathani, Associate Professor, Department of DravyaGuna, National Institute of Ayurveda , Madhav Vilas Palace, Jaipur - 302002 (Rajasthan).
11.	Dr. F. S. Shernani, Professor and Dean, Aligarh Muslim University, Aligarh, Uttar Pradesh.
12.	Dr. M. Krishnaveni, Professor, Gunapadam, Government Siddha Medical College, 6, Anna Arch Road, NSK Nagar, Arumbakkam Chennai, Tamil Nadu, 600106.
13.	Shri. Lal Hingorani, Pharmanza Herbal Private Limited, 214, BorsadTarapur Road, Near vadaldaPatia, Kaniya, Dharmaraj, Gujarat, India-388435.
14.	Dr. L. Sivakumar, SKM Siddha and Ayurveda Company Ltd., Saminathapuram, Erode, Tamilnadu
15.	Dr. Asad Mueed, Trustee and Governing body member of Hamdard National Foundation (India).
16.	Vd. Santosh Nevpurkar, Deerghayu Ayurved Swasthyalay,Nandigram colony, Garkheda, Aurangabad- 431005.
17.	Dr. P. Selva Shunmugam, President, Global Centre for Siddha, 3A, 1, Park street, Kilpauk Garden, Chennai- 600017.
18.	Dr. Sabahat Ullah Amoroha , H. No. 134 Qazizada Street Amoroha, Uttar Pradesh.
Special Invitee (s)	
19.	Dr. Sangeeta A. Duggal, Adv.(H), Ministry of Ayush
20.	Dr. Anil Khurana, Chairperson, NCH

21.	Dr. Subhash Kaushik, DG, CCRH
22.	Dr. Padma Gurmeet, Director, NISR
Other official(s)	
23.	Dr. Rachna Paliwal, Assistant Drug Controller (H.), AYUSH Vertical, CDSCO
24.	Dr. Ramavtar Sharma, Research Officer (Ay.), Office of DDGAyush
25.	Dr. Raman Kaushik, Research Officer(Ay.),, Drug Policy Section
ASUDTAB Members who could not attend the meeting	
1.	Prof. Tajuddin, Department of IlmulAdvia, Aligarh Muslim University, Aligarh
2.	Dr. G. Veluchamy, 24, Chokkanathar Street, Kartjikeyan Nagar, Maduravoyal, Chennai-602102